PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022SummaryGlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022 To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170312 For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

1. PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines France Drug
Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the
gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and
effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is
dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis
Menveo, account for the vast majority of global sales, with the US adolescent market being the key target
segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the
launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that
better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market
share during 2012-2022.
GlobalData does not expect relative patient share to change within the MenC conjugate space because Nuron
Biotechs Meningitec, Novartis Menjugate kit, and Baxters NeisVac-C all possess similar clinical profiles and
price points. The MenC conjugate patient share is largely determined by prescriber preference in France and
therefore is not expected to change drastically during the forecast period. The French government has
expressed disappointment with the low coverage rates of its MenC immunization program and is expected to
renew efforts to expand vaccine use (Stahl et al., 2013). In general, the sales potential in France is derived
from the immunization recommendations, which largely determine vaccine usage.
Scope
Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key
drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis. Sales
forecast for the top drugs in France from 2012-2022. Analysis of the impact of key events as well the drivers
and restraints affecting France Meningococcal Vaccines market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of
the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively
plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make
more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales
forecast for drugs from 2012-2022 in France
table Of Contents
1 Table Of Contents 1
1.1 List Of Tables 3
1.2 List Of Figures 3
2 Executive Summary 4
2.1 Sales For Meningococcal Vaccine In France 4
2.2 What Do The Physicians Think? 5
PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

2. 3 Introduction 6
3.1 Catalyst 6
3.2 Related Reports 7
3.3 Upcoming Related Reports 8
4 Disease Overview 9
4.1 Etiology And Pathophysiology 10
4.1.1 Etiology 10
4.1.2 Pathophysiology 11
4.2 Symptoms 13
4.3 Prognosis 14
5 Disease Management 14
5.1 Meningococcal Immunization Policy 15
5.2 France 17
5.2.1 Meningococcal Immunization Recommendations And Policies 17
5.2.2 Clinical Practice 19
6 Competitive Assessment 19
6.1 Overview 19
6.2 Strategic Competitor Assessment 20
6.3 Product Profiles Major Brands 21
6.3.1 Menveo 21
6.3.2 Nimenrix 25
6.3.3 Meningitec 28
6.3.4 Menjugate 31
6.3.5 Neisvac-c 34
6.3.6 Bexsero 37
7 Opportunity And Unmet Need 39
7.1 Overview 39
7.2 Unmet Needs 40
7.2.1 Unmet Need: Protection Against Serogroup B Disease 40
7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 40
7.2.3 Unmet Need: More Cost-effective Vaccines 42
7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 43
7.2.5 Unmet Need: Immunogenic Infant Vaccines 44
7.2.6 Unmet Need: Improved Vaccination Coverage Rates 45
7.2.7 Unmet Need: Increased Patient Awareness And Education 46
7.3 Unmet Needs Gap Analysis 47
7.4 Opportunities 48
7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 48
7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 49
PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

3. 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging
Markets 50
8 Pipeline Assessment 50
8.1 Overview 50
8.2 Promising Vaccines In Clinical Development 50
8.2.1 Mnb Rlp2086 54
8.3 Promising Vaccines In Early Clinical Development 59
8.3.1 Meninge Acyw Conj. 60
8.3.2 Menabcwy 64
8.3.3 Menc Conjugate 67
8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 70
9 Market Outlook 72
9.1 France 72
9.1.1 Forecast 72
9.1.2 Key Events 76
9.1.3 Drivers And Barriers 77
10 Appendix 78
10.1 Bibliography 78
10.2 Abbreviations 90
10.3 Methodology 92
10.4 Forecasting Methodology 92
10.4.1 Vaccine Coverage 93
10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 93
10.4.3 Vaccines Included 94
10.4.4 Key Launch Dates 95
10.4.5 General Pricing Assumptions 96
10.4.6 Individual Vaccine Assumptions 97
10.4.7 Pricing Of Pipeline Agents 102
10.5 Physicians And Specialists Included In This Study 103
10.6 About The Authors 107
10.6.1 Authors 107
10.6.2 Reviewers 107
10.6.3 Global Head Of Healthcare 107
10.7 About Globaldata 109
10.8 Contact Us 109
10.9 Disclaimer 109
Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most
comprehensive collection of market research reports. Marketresearchreports.biz services are especially
designed to save time and money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription access and consulting services.
PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

4. We serve all sizes and types of companies spanning across various industries.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.com
Website: www.marketresearchreports.biz
PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022